Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing April 06,…
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin…
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with…
February 22, 2026 16:00 ET | Source: Dyne Therapeutics, Inc. - Late-breaking poster to feature new positive cardiopulmonary function results…
ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced…
CANTON, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and…
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its…
CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company…
November 02, 2025 19:00 ET | Source: HUTCHMED (China) Limited — HUTCHMED unveils its innovative ATTC platform, potentially providing precision…
SOMERSET, N.J., Sept. 30, 2025 /PRNewswire/ -- VCTI, a technology and analytics company transforming data into broadband opportunity, today announced…